SeaStar Medical Q2 net loss $2.0M; NEUTRALIZE-AKI trial over 60% enrolled

SeaStar Medical Holding Corp

2025-Q2 EPS reported -$0.58 revenue$631,000

Net revenue $0.3M from QUELIMMUNE sales; net loss $2.0M ($0.18/share) vs $3.2M loss year ago.
NEUTRALIZE-AKI trial enrolled 125 of 200 patients; interim DSMB recommendations expected Q3 2025.
Three new children's hospitals adopted QUELIMMUNE; SAVE registry shows 75% 28-day survival in 20 pediatric patients.
Raised $12.4M in June and $8.4M in two July/August 2025 offerings; cash at June 30 was $6.3M.
CMS agreed to cover clinical trial expenses for NEUTRALIZE-CRS; DoD awarded $2M grant for burn research.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.